September 25, 2020

The Niche

Knoepfler lab stem cell blog

Korean FDA

2 min read

The Korean-based stem cell biotech, RNL Bio, which also does business in the U.S. as RNL Bio and Human Biostar Inc, reportedly (seems to be a press release, PR) has filed an investigational new drug (IND) application with the Korean FDA (KFDA). The purpose of the application is to test the efficacy of autologous adult stem cells for the treatment of cerebral palsy. In the PR, it says the trial would treat up to 45 children using a product called RNL-AstrostemTM given intravenously (IV). By way of …Read More